Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1
about
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infectionImpact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.Germline-targeting immunogens.Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
P2860
Q33205911-66A42B08-FA51-4A2A-80B4-17F5B1243A54Q33262382-AEA46362-09A4-44E1-951A-FDA466EDB1A3Q34203163-FD4869E9-AC73-4BCB-8DEC-971F4EF5FE02Q34432690-AEDCF656-E1CE-41F7-BBDB-38E2F484BFECQ34553676-F79E1E7D-8017-4D7E-8D72-E3FC36836BE1Q35635163-589D16E2-7733-420A-8407-795338D756D8Q35785244-587DEAF9-B14B-477A-B2A8-253DE9B77B70Q35857683-E96A9EFA-02DF-4126-B4E9-50FBC7BF0029Q36491733-61B875E1-A2D7-4BF5-B80C-4C4A684B3AF5Q38764547-585AD913-C991-4CE7-B93F-90815A0AEC56Q39305772-F8587F7D-8C09-4996-B103-68931927CB6EQ40721814-13DEBB46-83F7-4E1A-B9FC-D6D0E755CDE7
P2860
Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Multiple interactions across t ...... immunodeficiency virus type 1
@ast
Multiple interactions across t ...... immunodeficiency virus type 1
@en
type
label
Multiple interactions across t ...... immunodeficiency virus type 1
@ast
Multiple interactions across t ...... immunodeficiency virus type 1
@en
prefLabel
Multiple interactions across t ...... immunodeficiency virus type 1
@ast
Multiple interactions across t ...... immunodeficiency virus type 1
@en
P2093
P2860
P1433
P1476
Multiple interactions across t ...... immunodeficiency virus type 1
@en
P2093
Dimiter S Dimitrov
Gerald V Quinnan
Igor A Sidorov
Maria Leavitt
Peng Fei Zhang
Peter Bouma
P2860
P304
P356
10.1128/JVI.77.14.8061-8071.2003
P407
P577
2003-07-01T00:00:00Z